A team led by Mirang Kim and Seon-Young Kim from the Korea Research Institute of Bioscience and Biotechnology in Daejeon, South Korea, analyzed non-small-cell lung cancers that contain modified versions of a gene called ALK and have acquired resistance to a leading drug that inhibits the ALK protein. This evidence concerns the gene ALK and non-small cell lung carcinoma.